Photo: nasdaq.com
Mazdutide Outshines Semaglutide in Weight Loss and HbA1c in Phase 3 Trial
Innovent Biologics Inc. announced that mazdutide, a dual GLP-1 and glucagon receptor agonist, outperformed semaglutide in a Phase 3 trial, achieving significant weight loss and HbA1c reductions in type 2 diabetes patients.
- In the DREAMS-3 trial, 48.0% of patients treated with mazdutide reached an HbA1c level below 7.0% at week 32, marking a key clinical endpoint for diabetes management.
- Mazdutide, a dual agonist targeting both glucagon-like peptide-1 and glucagon receptors, demonstrated superior efficacy compared to semaglutide in patients with type 2 diabetes and obesity.
- This Phase 3 trial, the fourth in the phases of clinical research for mazdutide, underscores its potential as a breakthrough in obesity and type 2 diabetes treatment.
Why It Matters
The successful results of mazdutide in this Phase 3 trial could reshape diabetes management strategies, offering a promising alternative to existing therapies like semaglutide and addressing the growing obesity epidemic.